Site map
- bioTheranostics
bioTheranostics privacy statement
Contact us
Notice of privacy practices
Privacy policy
Products
Site map
Terms and conditions
About Us
About bioTheranostics
Press room
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
bioTheranostics Announces Commercial Agreement with Ferrer inCode to Market CancerTYPE ID® Molecular Cancer Classifier in Spain, Portugal, Greece, and Venezuela
bioTheranostics Announces Commercial Agreement with Lab21 to Market CancerTYPE ID® Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
bioTheranostics Announces Commercial Availability of Expanded Tumor-Type Database for CancerTYPE ID® and the Launch of KRAS Testing
bioTheranostics confirms that combination of two molecular biomarkers improves prediction of disease recurrence in early stage breast cancer patients
bioTheranostics presents at 2007 BIOCOM Investor Conference
Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
CONNECT Announces Finalists For 20th Annual Most Innovative New Product Awards
Data from Clinical Studies of bioTheranostics’ CancerTYPE ID and Breast Cancer Index Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting
Data from Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
Data from Three Clinical Studies of bioTheranostics’ Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
Study Links HOXB13 & IL17BR with Estrogen Signaling in Breast Cancer
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
Arcturus Partnership Gives Agendia European Rights to TUO Gene Expression Profile for CupPrintT Diagnostic Test
bioTheranostics Announces CAP Accreditation of Its Laboratory Operations
bioTheranostics Carcinoma of Unknown Primary (CUP) Technology Highlighted in Case Study Published in New England Journal of Medicine
Oncology Social Workers Report “Uncertain” and “Unknown” Cancers Significantly Increase Patient Distress
Quest Diagnostics Launches Test to Help Oncologists Predict Risk of Breast Cancer Recurrence in Women with Estrogen Receptor (ER)-Positive, Lymph Node- Negative Cancers
bioTheranostics has a rich history of innovation
bioTheranostics guiding principles
Management team
bioTheranostics careers
Changing the way you see cancer patients
Patients
Healthcare Professionals
Ordering A Test
+1 (877) 886-6739 client services
